Registry of Asthma Patients Initiating DUPIXENT®
RAPID
3 other identifiers
observational
718
10 countries
128
Brief Summary
The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of:
- Patient demographics (eg, gender, age, and race)
- Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are:
- To characterize real-world use patterns of DUPIXENT® for asthma
- To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting
- To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT®
- To collect long-term safety data on study participants in the real-world setting
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2020
Longer than P75 for all trials
128 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 25, 2020
CompletedFirst Posted
Study publicly available on registry
February 27, 2020
CompletedStudy Start
First participant enrolled
March 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 27, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 27, 2026
CompletedFebruary 27, 2026
February 1, 2026
6.2 years
February 25, 2020
February 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Demography
Including gender, age, race
At Baseline
Baseline Characteristics
Including prior medications and procedures, medical history, asthma history, weight, height
At Baseline
Secondary Outcomes (14)
Baseline Treatment Characteristics
At Baseline
Incidence of adverse events (AEs)
Baseline up to 3 years
Physician Assessment: - Spirometry
Baseline up to 3 years
Physician Assessment: Fractional exhaled Nitric Oxide (FeNO)
Baseline up to 3 Years
Patient Reported Outcome: Asthma Control Questionnaire, 6-item (ACQ-6)
Baseline up to 3 Years
- +9 more secondary outcomes
Interventions
There is no investigational product provided by the study sponsor and no therapeutic intervention regulated by this protocol. As a condition for eligibility, patients are required to initiate DUPIXENT® for asthma, according to the country-specific prescribing information, prescribed by their physician as part of their normal care (ie, not for the purpose of enrolling in the registry). Once patients enter the study, there are no protocol requirements regarding DUPIXENT® or any other treatments.
Eligibility Criteria
The target population comprises adult and adolescent patients (male or female, ≥12 years old), who are initiating treatment with DUPIXENT® for asthma according to the country-specific prescribing information.
You may qualify if:
- Willing and able to comply with the required clinic visits, study procedures and assessments
- Able to understand and complete study-related questionnaires
- Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required
- Initiating treatment with DUPIXENT® for a primary indication of asthma according to the country-specific prescribing information
You may not qualify if:
- Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information
- Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
- Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Regeneron Pharmaceuticalslead
- Sanoficollaborator
Study Sites (128)
Clinical Research Center of Alabama, LLC
Birmingham, Alabama, 35209, United States
Arizona Allergy & Immunology Research
Gilbert, Arizona, 85234, United States
Medical Research of Arizona, a Division of Allergy, Asthma & Immunology Associates, Ltd.
Scottsdale, Arizona, 85251, United States
Children's Hospital of Orange County
Orange, California, 92868, United States
Riviera Allergy Medical Center
Redondo Beach, California, 90277, United States
Allergy & Asthma Medical Group and Research, A PC
San Diego, California, 92123, United States
Bensch Clinical Research, LLC
Stockton, California, 95207, United States
Allianz Research Institute, Inc.
Westminster, California, 92683, United States
Global Research Solutions
Hollywood, Florida, 33021, United States
Memorial Healthcare System
Hollywood, Florida, 33021, United States
Clinical Research Specialists, LLC
Kissimmee, Florida, 34746, United States
Kratz Allergy & Asthma
Port Richey, Florida, 34653, United States
GCP, Global Clinical Professionals
St. Petersburg, Florida, 33702, United States
Allergy & Asthma Diagnostic Treatment Center
Tallahassee, Florida, 32308, United States
Omni Allergy
Atlanta, Georgia, 30342, United States
Columbus Regional Research Institute
Columbus, Georgia, 31904, United States
IACT Health Southeast Lung Associates
Rincon, Georgia, 31326, United States
Treasure Valley Medical Research
Boise, Idaho, 83706, United States
Northwestern Medical Group Allergy & Immunology Clinic
Chicago, Illinois, 60611, United States
The University of Chicago
Chicago, Illinois, 60634, United States
NorthShore University Health System
Evanston, Illinois, 60201, United States
Asthma and Allergy Center of Chicago
Oak Park, Illinois, 60301, United States
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, 46202, United States
Velocity Clinical Research
Overland Park, Kansas, 66210, United States
Dr. Henry J. Kanarek Allergy, Asthma & Immunology
Overland Park, Kansas, 66211, United States
Family Allergy and Asthma
Louisville, Kentucky, 40291, United States
Allergy & Asthma Specialists, PSC
Owensboro, Kentucky, 42301, United States
Schreiber Allergy
Rockville, Maryland, 20850, United States
Virgo-Carter Pediatrics
Silver Spring, Maryland, 20910, United States
Chesapeake Clinical Research, Inc.
White Marsh, Maryland, 21162, United States
University of Michigan Allergy Specialty Clinic and Food Allergy Clinic
Ann Arbor, Michigan, 48106, United States
University of Michigan
Ann Arbor, Michigan, 48109, United States
Allergy and Asthma Center of Minnesota
Maplewood, Minnesota, 55109, United States
Mayo Clinic
Rochester, Minnesota, 55905, United States
University of Mississippi Medical Center
Jackson, Mississippi, 39216, United States
ENT & Allergy Center of Missouri
Columbia, Missouri, 65201, United States
St. Louis Children's Hospital
St Louis, Missouri, 63110, United States
The Clinical Research Center, LLC
St Louis, Missouri, 63141, United States
Nebraska Medical Research Institute, Inc.
Bellevue, Nebraska, 68123, United States
CHI Health Clinic Pulmonary
Omaha, Nebraska, 68124, United States
Ocean Allergy & Respiratory Research Center
Brick, New Jersey, 08724, United States
Atlantic Research Center, LLC
Ocean City, New Jersey, 07712, United States
A Atat Progressive Pulmonary & Sleep Medicine
Brooklyn, New York, 11209, United States
New York Allergy and Sinus Centers
Glendale, New York, 11385, United States
Northwell Health Division of Allergy & Immunology
Great Neck, New York, 11021, United States
Northwell Health Physician Partners Pulmonary Medicine and Cardiology at Manhasset
Manhasset, New York, 11030, United States
NYU Langone Hospital - Long Island
Mineola, New York, 11501, United States
Summit Health
Oakland Gardens, New York, 11364, United States
RRH Allergy, Immunology & Rheumatology
Rochester, New York, 14607, United States
Allergy & Asthma Care of LI
Rockville Centre, New York, 11570, United States
Montefiore Medical Center
The Bronx, New York, 10461, United States
Allergy Partners of Western North Carolina
Asheville, North Carolina, 28801, United States
Allergy Partners of the Triangle
Cary, North Carolina, 27518, United States
UNC Children's Hospital
Chapel Hill, North Carolina, 27599, United States
Javara Inc. and Tryon Medical Partners, PLLC
Charlotte, North Carolina, 28210, United States
Airways Clinical Research Center
Winston-Salem, North Carolina, 27104, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45220, United States
Allergy, Asthma and Clinical Research Center
Oklahoma City, Oklahoma, 73120, United States
Oklahoma Institute of Allergy and Asthma Clinical Research, LLC
Oklahoma City, Oklahoma, 73131, United States
Portland Research
Happy Valley, Oregon, 97086, United States
Allergy and Asthma Specialists, P.C.
Blue Bell, Pennsylvania, 19422, United States
Columbo Asthma, Allergy and Immunology, LLC
Bryn Mawr, Pennsylvania, 19010, United States
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212, United States
Asthma, Nasal Disease & Allergy Research Center of New England
East Providence, Rhode Island, 02914, United States
National Allergy and Asthma Research, LLC
North Charleston, South Carolina, 29420, United States
Charleston ENT Associates, LLC
Summerville, South Carolina, 29486, United States
Precision Research Institute, LLC
Houston, Texas, 77029, United States
STAAMP Research, LLC
San Antonio, Texas, 78229, United States
Element Research Group
San Antonio, Texas, 78258, United States
Tanner Clinic
Layton, Utah, 84041, United States
Allergy Associates of Utah
Murray, Utah, 84107, United States
Seattle Allergy & Asthma Research Institute
Seattle, Washington, 98115, United States
Gundersen Health System
La Crosse, Wisconsin, 54601, United States
The University of British Columbia
Vancouver, British Columbia, V5Z 1M9, Canada
St. Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6, Canada
BLC Clinical Research
Burlington, Ontario, L7N 3V2, Canada
Evidence Based Medical Educator Inc.
Toronto, Ontario, M5G 1E2, Canada
Inspiration Research Limited
Toronto, Ontario, M5T 3A9, Canada
Dr. Syeed Anees Medicine Professional Corporation
Windsor, Ontario, N8X 1T3, Canada
Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) - Universite Laval
Québec, G1V 4G5, Canada
Sygehus Lillebaelt - Vejle Sygehus - Lungemedicinsk afdeling
Vejle, 7100, Denmark
Centre Hospitalier du Pays d'Aix - Maladies Respiratoires
Aix-en-Provence, 13100, France
CHU de Bordeaux
Bordeaux, 33076, France
Centre Hospitalier Universitaire Dijon Bourgogne (CHU Dijon) - Hôpital Francois Mitterrand
Dijon, 21079, France
Hôpital de la Croix-Rousse
Lyon, 69317, France
Hôpital Nord
Marseille, 13015, France
Hopital Jacques Monod
Montivilliers, 76290, France
Fondazione Salvatore Maugeri
Bari, Apulia, 70020, Italy
Ospedale dei Bambini Vittore Buzzi ASST Fatebenefratelli Sacco
Milan, Lombardy, 20154, Italy
Ospedale Luigi Sacco, PU, ASST Fatebenefratelli Sacco
Milan, Lombardy, 20157, Italy
La Fondazione IRCCS Policlinico "San Matteo"
Pavia, Lombardy, 27100, Italy
Istituto Clinico Himanitas, Humanitas Mirasole S.p.a.
Rozzano, Lombardy, 20089, Italy
Azienda Sanitaria Locale Salerno
Battipaglia, Salerno, 84091, Italy
Istituto Nazionale di Riposo e Cura per Anziani
Ancona, The Marches, 60127, Italy
Hansaki Clinic
Kiyosu-shi, Aichi-ken, 452-0001, Japan
Hokkaido University Hospital
Kita-ku, Hokkaido, 060-8648, Japan
Kobe University Hospital
Kobe, Hyōgo, 650-0017, Japan
Dokkyo Medical University Hospital
Mibu, Tochigi, 321-0293, Japan
Juntendo University Hospital
Bunkyo-ku, Tokyo, 113-0033, Japan
Incorporated Medical Corporation, Shishin Iryokai, Respiratory Care Clinic Tokyo
Chuo-ku, Tokyo, 104-0031, Japan
Teikyo University Hospital
Itabashi-ku, Tokyo, 173-8606, Japan
Nihon University Itabashi Hospital
Itabashi-ku, Tokyo, 173-8610, Japan
Incorporated Medical Corporation, Jinyukai, Jinyu Clinic
Nakano Ku, Tokyo, 164-0012, Japan
Showa University Hospital
Shinagawa-ku, Tokyo, 142-8666, Japan
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo, 162-8666, Japan
The Fraternity Memorial Hospital
Sumida-ku, Tokyo, 130-8587, Japan
Agosto Allergy and Immunology
Cayey, 00736, Puerto Rico
CardioPulmonary Research CSP
Guaynabo, 00968, Puerto Rico
Instituto Pulmonary Diseases Torre Medica San Lucas
Ponce, 00731, Puerto Rico
Rafael H Zaragoza - Urdaz
San Juan, 00918, Puerto Rico
Fundacion de Investigacion de Diego
San Juan, 00927, Puerto Rico
University of Puerto Rico Medical Sciences Campus
San Juan, 00936, Puerto Rico
Hospital De La Santa Creu I Sant Pau
Barcelona, Catalonia, 08025, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Catalonia, 08035, Spain
Hospital Germans Trias i Pujol
Barcelona, Catalonia, 08916, Spain
Complexo Hospialario Universitario A Coruña
A Coruña, Galicia, 15006, Spain
Fysikalisk Medicin
Lidingö, Stockholms Län [se-01], SE-181 58, Sweden
Pennine Acute Hospitals NHS Trust
Manchester, Greater Manchester, M8 5RB, United Kingdom
University Hospitals Birmingham NHS Foundation Trust
Birmingham, B9 5SS, United Kingdom
Royal Devon University Healthcare NHS Foundation Trust
Exeter, EX2 5DW, United Kingdom
Gartnavel General Hospital
Glasgow, G12 0YN, United Kingdom
St. James Hospital Leeds
Leeds, LS9 7TF, United Kingdom
Glenfield General Hospital
Leicester, LE3 9QP, United Kingdom
St. Bartholomew's Hospital
London, EC1A 7BE, United Kingdom
Guy's Hospital
London, SE1 9RT, United Kingdom
Wythenshawe Hospital
Manchester, M23 9QZ, United Kingdom
Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, NG5 1PD, United Kingdom
Related Publications (1)
Gall R, Jain N, Soong W, Settipane RA, Xia C, Zhang Y, Haselkorn T, Jacob-Nara JA, Siddiqui S. Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry. Adv Ther. 2023 Mar;40(3):1292-1298. doi: 10.1007/s12325-022-02399-5. Epub 2023 Jan 10.
PMID: 36626107DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trial Management
Regeneron Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 156 Weeks
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 25, 2020
First Posted
February 27, 2020
Study Start
March 2, 2020
Primary Completion
April 27, 2026
Study Completion
April 27, 2026
Last Updated
February 27, 2026
Record last verified: 2026-02